Parameters of mineral metabolism predict midterm clinical outcome in end-stage heart failure patients

Scand Cardiovasc J. 2011 Dec;45(6):342-8. doi: 10.3109/14017431.2011.611250. Epub 2011 Sep 12.

Abstract

Objectives: We investigated to which extent disturbances in mineral metabolism predict 90-day clinical outcome in end-stage heart failure patients.

Design: Among numerous biochemical parameters, we measured serum levels of sodium and magnesium, the calciotropic hormones parathyroid hormone and 1,25-dihydroxyvitamin D as well as fibroblast growth factor-23 (a phosphaturic hormone) in 305 cardiac transplant candidates. Primary endpoint was a composite of the need of mechanical circulatory support (MCS), transplantation, or death.

Results: Of the study cohort, 33.4% reached the primary endpoint. In detail, 19% were transplanted (the vast majority was listed "high urgent"), 8.8% died and 5.6% received MCS implants. As determined by logistic regression analysis, all aforementioned biochemical parameters were independently related to the primary endpoint. Results did not change substantially when transplanted patients were censored. A risk score (0-5 points) was developed. Of the patients who scored 5 points 89.5% reached the primary endpoint whereas of the patients with a zero score only 3.8% reached the primary endpoint.

Conclusions: Our data demonstrate that in addition to the well-known predictive value of disturbed sodium metabolism, derangements in calcium, phosphate, and magnesium metabolism also predict midterm clinical outcome in end-stage heart failure patients.

MeSH terms

  • Biomarkers / blood
  • Disease-Free Survival
  • Female
  • Fibroblast Growth Factor-23
  • Fibroblast Growth Factors / blood
  • Germany
  • Heart Failure / blood*
  • Heart Failure / mortality
  • Heart Failure / therapy
  • Heart Transplantation
  • Heart-Assist Devices
  • Humans
  • Kaplan-Meier Estimate
  • Logistic Models
  • Magnesium / blood
  • Male
  • Metabolic Diseases / blood*
  • Metabolic Diseases / mortality
  • Metabolic Diseases / therapy
  • Middle Aged
  • Parathyroid Hormone / blood
  • Pilot Projects
  • Prognosis
  • Risk Assessment
  • Risk Factors
  • Sodium / blood
  • Time Factors
  • Vitamin D / analogs & derivatives
  • Vitamin D / blood

Substances

  • Biomarkers
  • PTH protein, human
  • Parathyroid Hormone
  • Vitamin D
  • Fibroblast Growth Factors
  • 1,25-dihydroxyvitamin D
  • Fibroblast Growth Factor-23
  • Sodium
  • Magnesium